Literature DB >> 10369457

Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.

I Verde1, G Vandecasteele, F Lezoualc'h, R Fischmeister.   

Abstract

The effects of several phosphodiesterase (PDE) inhibitors on the L-type Ca current (I(Ca)) and intracellular cyclic AMP concentration ([cAMP]i) were examined in isolated rat ventricular myocytes. The presence of mRNA transcripts encoding for the different cardiac PDE subtypes was confirmed by RT-PCR. IBMX (100 microM), a broad-spectrum PDE inhibitor, increased basal I(Ca) by 120% and [cAMP]i by 70%, similarly to a saturating concentration of the beta-adrenoceptor agonist isoprenaline (1 microM). However, MIMX (1 microM), a PDE1 inhibitor, EHNA (10 microM), a PDE2 inhibitor, cilostamide (0.1 microM), a PDE3 inhibitor, or Ro20-1724 (0.1 microM), a PDE4 inhibitor, had no effect on basal I(Ca) and little stimulatory effects on [cAMP]i (20-30%). Each selective PDE inhibitor was then tested in the presence of another inhibitor to examine whether a concomitant inhibition of two PDE subtypes had any effect on I(Ca) or [cAMP]i. While all combinations tested significantly increased [cAMP]i (40-50%), only cilostamide (0.1 microM)+ Ro20-1724 (0.1 microM) produced a significant stimulation of I(Ca) (50%). Addition of EHNA (10 microM) to this mix increased I(Ca) to 110% and [cAMP]i to 70% above basal, i.e. to similar levels as obtained with IBMX (100 microM) or isoprenaline (1 microM). When tested on top of a sub-maximal concentration of isoprenaline (1 nM), which increased I(Ca) by (approximately 40% and had negligible effect on [cAMP]i, each selective PDE inhibitor induced a clear stimulation of [cAMP]i and an additional increase in I(Ca). Maximal effects on I(Ca) were approximately 8% for MIMX (3 microM), approximately 20% for EHNA (1-3 microM), approximately 30% for cilostamide (0.3-1 microM) and approximately 50% for Ro20-1724 (0.1 microM). Our results demonstrate that PDE1-4 subtypes regulate I(Ca) in rat ventricular myocytes. While PDE3 and PDE4 are the dominant PDE subtypes involved in the regulation of basal I(Ca), all four PDE subtypes determine the response of I(Ca) to a stimulus activating cyclic AMP production, with the rank order of potency PDE4>PDE3>PDE2>PDE1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369457      PMCID: PMC1565993          DOI: 10.1038/sj.bjp.0702506

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

Review 1.  Cyclic AMP phosphodiesterases and Ca2+ current regulation in cardiac cells.

Authors:  R Fischmeister; H C Hartzell
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

2.  Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes.

Authors:  P F Méry; S M Lohmann; U Walter; R Fischmeister
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

3.  Species-dependent differences in the properties of particulate cyclic nucleotide phosphodiesterase from rat and rabbit ventricular myocardium.

Authors:  M Shahid; M Wilson; C D Nicholson; R J Marshall
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

4.  Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development.

Authors:  B Grimaldi; A Bonnin; M P Fillion; M Ruat; E Traiffort; G Fillion
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-04       Impact factor: 3.000

5.  Methylxanthine inhibitors of phosphodiesterases.

Authors:  J N Wells; J R Miller
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

6.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

7.  Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells.

Authors:  R Fischmeister; H C Hartzell
Journal:  Mol Pharmacol       Date:  1990-09       Impact factor: 4.436

8.  Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.

Authors:  B Muller; C Lugnier; J C Stoclet
Journal:  J Cardiovasc Pharmacol       Date:  1990-11       Impact factor: 3.105

9.  Cyclic GMP regulates the Ca-channel current in guinea pig ventricular myocytes.

Authors:  R C Levi; G Alloatti; R Fischmeister
Journal:  Pflugers Arch       Date:  1989-04       Impact factor: 3.657

10.  Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue.

Authors:  D C Bode; J R Kanter; L L Brunton
Journal:  Circ Res       Date:  1991-04       Impact factor: 17.367

View more
  60 in total

1.  Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload.

Authors:  Jerome Piquereau; Fanny Caffin; Marta Novotova; Alexandre Prola; Anne Garnier; Philippe Mateo; Dominique Fortin; Le Ha Huynh; Valérie Nicolas; Marcel V Alavi; Catherine Brenner; Renée Ventura-Clapier; Vladimir Veksler; Frédéric Joubert
Journal:  Cardiovasc Res       Date:  2012-03-08       Impact factor: 10.787

2.  A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.

Authors:  Francesca Rochais; Aniella Abi-Gerges; Kathleen Horner; Florence Lefebvre; Dermot M F Cooper; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

3.  The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3.

Authors:  Cecile Terrenoire; Miles D Houslay; George S Baillie; Robert S Kass
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

4.  Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.

Authors:  Tatiana M Vinogradova; Syevda Sirenko; Yevgeniya O Lukyanenko; Dongmei Yang; Kirill V Tarasov; Alexey E Lyashkov; Nevin J Varghese; Yue Li; Khalid Chakir; Bruce Ziman; Edward G Lakatta
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-06

5.  All preconditioning-related G protein-coupled receptors can be demonstrated in the rabbit cardiomyocyte.

Authors:  Wenkuan Xin; Xiulan Yang; Thomas C Rich; Thomas Krieg; Robert Barrington; Michael V Cohen; James M Downey
Journal:  J Cardiovasc Pharmacol Ther       Date:  2011-08-09       Impact factor: 2.457

6.  Phosphodiesterase 4B in the cardiac L-type Ca²⁺ channel complex regulates Ca²⁺ current and protects against ventricular arrhythmias in mice.

Authors:  Jérôme Leroy; Wito Richter; Delphine Mika; Liliana R V Castro; Aniella Abi-Gerges; Moses Xie; Colleen Scheitrum; Florence Lefebvre; Julia Schittl; Philippe Mateo; Ruth Westenbroek; William A Catterall; Flavien Charpentier; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

7.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

8.  Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes.

Authors:  Mark T Ziolo; Susanne J Lewandowski; Jacquelyn M Smith; Fred D Romano; Gordon M Wahler
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

10.  PDE4 in the human heart - major player or little helper?

Authors:  Thomas Eschenhagen
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.